Please login to the form below

Not currently logged in
Email:
Password:

Zostavax

This page shows the latest Zostavax news and features for those working in and with pharma, biotech and healthcare.

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

CDC backs GSK’ s Shingrix over Merck &Co’ s Zostavax. US advisors recommend GSK's shingle vaccine be used instead of Merck's rival product. ... Prospects for GlaxoSmithKline’s new shingle vaccine Shingrix have been raised after US advisors

Latest news

  • GSK’s shingles vaccine Shingrix claims US approval GSK’s shingles vaccine Shingrix claims US approval

    GSK’ s shingles vaccine Shingrix claims US approval. Becomes first alternative to Merck &Co’s Zostavax. ... The FDA has approved Shingrix for the prevention of shingles in adults aged 50 years and older, and it becomes the first alternative to Merck

  • GSK's Shingrix sails through FDA advisory committee GSK's Shingrix sails through FDA advisory committee

    It is increasingly common with advancing age. GSK is hoping that increased efficacy means it will be favoured ahead of Zostavax and also drive up vaccination rates against shingles, which remain ... In June, the company reported the results of a trial

  • GSK makes case for revaccination with Shingrix GSK makes case for revaccination with Shingrix

    The results of the Zoster-048 study met its primary objective of showing that people who had received the currently-approved vaccine - Merck &Co's Zostavax - at least five years previously ... after clinical data demonstrated the drug's greater efficacy

  • GSK files shingles vaccine Shingrix in Europe GSK files shingles vaccine Shingrix in Europe

    GSK files shingles vaccine Shingrix in Europe. Blockbuster hopeful would compete with Merck &Co’ s Zostavax. ... By contrast, Zostavax - currently the only shingles vaccine on the market - has an efficacy of between 18% and 70% and is both less

  • GSK's blockbuster hopeful Shingrix filed in US GSK's blockbuster hopeful Shingrix filed in US

    In contrast, Zostavax' efficacy is generally between 18% and 70% and is known to decline in older people. ... GSK is hoping that increased efficacy means it will be favoured ahead of Zostavax and also drive up vaccination rates against shingles, which

More from news
Approximately 4 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics